Author : Wagh Jyoti Gorakh 1
Date of Publication :17th August 2017
Abstract: Cancer being one of the most common types of disease affecting large number of population in the present day life, various drug molecules was developed against cancer where the cancer cells are being resistant to the drug molecules. Inhibition of apoptosis pathway is one of the leading causes of cancer, where there is uncontrolled growth of cells leading to the formation of tumors. C-FLIP is one of such protein which inhibits the apoptosis process, which can be considered as drug target by inhibiting the c-FLIP activity there will be increase in the apoptosis process which would be of potential use. In our present study we modeled c-FLIP protein contains death effector Domains (DED’s) and have taken some of natural and synthetic inhibitors that inhibit c-FLIP protein and studied the interaction studies of these ligand molecules with the protein. Among the taken 37 ligands 12 ligands were interacting with the c-FLIP protein. Among the synthetic compounds Droxinostat and in natural compounds Chyrasin are showing highest dock scores of 44.169 and 19.758. These studies could of potential use in generating new drug molecules by creating analogues with the highest interacting molecules
Reference :
-
- Hengartner MO. The biochemistry of apoptosis. Nature 2000; 407:770–6. [2] Kelley SK, Ashkenazi A. Targeting death receptors in cancer with Apo2L/TRAIL. Curr Opin Pharmacol 2004;4:333–9.
- Rowinsky EK. Targeted induction of apoptosis in cancer management: the emerging role of tumor necrosis factor-related apoptosis inducing ligand receptor activating agents. J Clin Oncol 2005;23: 9394 –407
- Krueger A, Baumann S, Krammer PH, Kirchhoff S. FLICE-inhibitory proteins: regulators of deathreceptor-mediate d apoptosis. Mol Cell Biol 2001;21: 8247–54
- Budd RC, YehWC , Tschopp J. cFLIP regulation of lymphocyte activation and development. Nat Rev Immunol 2006; 6:196– 204.
- Golks, A.; Brenner, D.; Fritsch, C.; Krammer, P. H.; Lavrik, I. N. c-FLIPR, a new regulator of death receptor-induced apoptosis. J. Biol. Chem. 2005, 280, 14507-14513.
- Tschopp, J.; Irmler, M.; Thome, M. Inhibition of Fas death signals by FLIPs. Curr. Opin. Immunol. 1998, 10, 552-558
- Wajant H. Targeting the FLICE inhibitory protein (FLIP) in cancer therapy. Mol Interv 2003;3:124–7.